To explore the potential role of PRDX6-iPLA2 in stroke, MJ33, an inhibitor of the iPLA2 activity of PRDX6, was used to inhibit PRDX6-iPLA2 after 60 min of MCAO, a rat model for stroke, then followed by 24 h of reperfusion. This evidence concerns the gene PLA2G6 and stroke disorder.